Dr. Philip A. Philip is Team Leader for Gastrointestinal Oncology and Professor of Medicine and Oncology, Wayne State University, Detroit, Michigan. OncologySTAT: In your view, which development in pancreatic cancer research could have the most significant impact in oncology?Dr. Philip: In my opinion, the French study (ACCORD 11/0402), which was a randomized phase III trial that compared FOLFIRINOX (5-FU, irinotecan, and oxaliplatin) with gemcitabine in patients with metastatic pancreatic cancer,...